neurology Archives

Exclusive By Kate Sheridan

Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s

Biotech By Matthew Herper

Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease

Biotech By Damian Garde

Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial

In the Lab By Elizabeth Cooney

New study revives a Mozart sonata as a potential epilepsy therapy

Pharmalot By Ed Silverman and Damian Garde

Veterans Affairs declines to cover Biogen’s Alzheimer’s drug over effectiveness, safety concerns

Biotech By Joanne Silberner

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

Pharmalot By Ed Silverman

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Pharmalot By Ed Silverman

Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug

Pharmalot By Ed Silverman

Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

Health By Megan Molteni

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?

Pharmalot By Ed Silverman

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

Pharmalot By Ed Silverman

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

Health By Elizabeth Cooney

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

Biotech By Nicholas Florko

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

Biotech By Felice J. Freyer — Boston Globe

What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead

Health By Erika Check Hayden

The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price

Pharmalot By Ed Silverman

Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year

Pharmalot By Ed Silverman

Biogen to expand access to its ALS drug, but move may come too late for some patients

Health By Sara Reardon

Covid-19 gave scientists an opening to better understand how brain disorders arise

Health Tech By Katie Palmer

A new crop of medical devices are trying to hack the vagus nerve to treat disease

Biotech By Adam Feuerstein

FDA wants more data on promising ALS drug, frustrating patients seeking faster access

First Opinion Podcast By Patrick Skerrett

Jason Karlawish and an Alzheimer’s caregiver on dementia’s ripple effect

Pharmalot By Ed Silverman

With time running out, an ALS patient fights with Biogen over expanded access to its drug

Pharmalot By Ed Silverman

Most Read

‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

6 ways the FDA’s approval of Aduhelm does more harm than good

Akili’s therapeutic video game will be tested as a treatment for Covid ‘brain fog’

1 in 3 Covid-19 patients are diagnosed with a neuropsychiatric condition in the next six months, large study finds

Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder

When Covid-19 hits the brain, it can cause strokes, psychosis and a dementia-like syndrome, new survey shows

Role of seizures in Alzheimer’s disease is gaining overdue attention

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

All Coverage

Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s

Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease

Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial

New study revives a Mozart sonata as a potential epilepsy therapy

Veterans Affairs declines to cover Biogen’s Alzheimer’s drug over effectiveness, safety concerns

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug

Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead

The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price

Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year

Biogen to expand access to its ALS drug, but move may come too late for some patients

Covid-19 gave scientists an opening to better understand how brain disorders arise

A new crop of medical devices are trying to hack the vagus nerve to treat disease

FDA wants more data on promising ALS drug, frustrating patients seeking faster access

Jason Karlawish and an Alzheimer’s caregiver on dementia’s ripple effect

With time running out, an ALS patient fights with Biogen over expanded access to its drug

Medicare spending on neurology drugs jumped, while number of claims barely budged